Приказ основних података о документу
The effects of anti-hypertensives and type 2 diabetes on salivary flow and total antioxidant capacity
dc.creator | Đukić, Ljiljana | |
dc.creator | Roganović, Jelena | |
dc.creator | Brajović, Milan | |
dc.creator | Bokonjić, Dejan | |
dc.creator | Stojić, Dragica | |
dc.date.accessioned | 2020-07-02T12:55:05Z | |
dc.date.available | 2020-07-02T12:55:05Z | |
dc.date.issued | 2015 | |
dc.identifier.issn | 1354-523X | |
dc.identifier.uri | https://smile.stomf.bg.ac.rs/handle/123456789/1961 | |
dc.description.abstract | ObjectiveThe present cross-sectional study aimed to determine the effect of first-line anti-hypertensive drugs (enalapril, metoprolol, and combinations of enalapril with metoprolol and/or hydrochlorothiazide) on salivary gland function and salivary total antioxidant capacity (TAC) in hypertensive patients with/without diabetes mellitus (DM) type 2. Materials and MethodsSalivary gland function was measured as xerostomia (interview) and unstimulated whole saliva flow rate (UWSFR) in 447 subjects (387 hypertensive and 60 healthy). Salivary TAC was evaluated by spectrophotometric assay. ResultsEnalapril is not xerogenic, while metoprolol and drug combinations are. In the presence of DM type 2, all drugs, except metoprolol, had pronounced xerogenic effect. Binary logistic regression analysis found enalapril to be significantly associated with decreased risk of xerogenic effect development, while DM type 2 with increased risk. In the presence of enalapril in hypertensive patients with/without DM type 2 salivary TAC was similar to that in healthy subjects, while for metoprolol was reduced. ConclusionsEnalapril is not xerogenic but is antioxidant, which moderately reduces the risk of xerogenic effect development even in the presence of DM type 2. However, metoprolol and drug combinations exhibit xerogenic effect. In DM type 2, xerogenic effect of all drugs was pronounced except of metoprolol. | en |
dc.publisher | Wiley, Hoboken | |
dc.relation | info:eu-repo/grantAgreement/MESTD/Basic Research (BR or ON)/175021/RS// | |
dc.rights | restrictedAccess | |
dc.source | Oral Diseases | |
dc.subject | anti-hypertensive drugs | en |
dc.subject | xerostomia | en |
dc.subject | salivary flow rate | en |
dc.subject | salivary total antioxidant capacity | en |
dc.subject | diabetes mellitus type 2 | en |
dc.title | The effects of anti-hypertensives and type 2 diabetes on salivary flow and total antioxidant capacity | en |
dc.type | article | |
dc.rights.license | ARR | |
dcterms.abstract | Бокоњић, Дејан; Ђукић, Љиљана; Брајовић, Милан; Рогановић, Јелена; Стојић, Драгица; | |
dc.citation.volume | 21 | |
dc.citation.issue | 5 | |
dc.citation.spage | 619 | |
dc.citation.epage | 625 | |
dc.citation.other | 21(5): 619-625 | |
dc.citation.rank | M21 | |
dc.identifier.wos | 000355741700010 | |
dc.identifier.doi | 10.1111/odi.12325 | |
dc.identifier.pmid | 25689395 | |
dc.identifier.scopus | 2-s2.0-84930277109 | |
dc.type.version | publishedVersion |
Документи
Датотеке | Величина | Формат | Преглед |
---|---|---|---|
Уз овај запис нема датотека. |